Investors looking at Financial - Investment Bank stocks probably know about Nomura Holdings (NMR) and Bank of America (BAC). However, which of these two stocks offers a better value opportunity for investors at this moment?
Last week, our proven methods helped investors successfully manage the market. Take a look at some of the successes we've had over the last three months.
At Zacks, we concentrate on the reliable Zacks Rank system, which highlights earnings estimates and changes in those estimates to identify excellent stocks. At the same time, we keep an eye on the most recent trends in value, growth, and momentum to support our top selections.
Nomura Holdings, Inc. (NYSE:NMR) will hold its Q3 2025 Earnings Conference Call on February 5, 2025, at 3:00 AM ET. The call will feature company participants, including Chief Financial Officer Takumi Kitamura, and various conference call participants from different securities firms. Please note that this call is being recorded as requested by the company.
Is Nomura Holdings (NMR) a strong choice for momentum investors? Let's take a closer look.
Investors looking at stocks in the Financial - Investment Bank sector may be familiar with Nomura Holdings (NMR) and Bank of America (BAC). However, which of these two stocks is more appealing to value investors?
Nomura (NMR) has formed a hammer chart pattern, suggesting that the stock has found support after a recent decline. Additionally, an increase in earnings estimate revisions may signal a potential trend reversal for the stock soon.
At Zacks, we concentrate on the reliable Zacks Rank system, which highlights earnings estimates and changes in those estimates to identify excellent stocks. However, we also keep an eye on the most recent trends in value, growth, and momentum to support our top selections.
CALGARY, AB, Dec. 11, 2024 /PRNewswire/ - Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), a leader in portable NMR instruments and MRI technology for industrial and research uses, has announced the results of a study by the United States Pharmacopeia (USP) that shows benchtop NMR is effective for quality control of active pharmaceutical ingredients (API). Sean Krakiwsky, the Founder and CEO of Nanalysis, stated that they believe benchtop NMR will soon play a significant role in the multi-billion-dollar pharmaceutical quality control market.
NEW YORK, Nov. 10, 2024 /PRNewswire/ -- Pomerantz LLP is looking into claims for investors of Nomura Holdings, Inc. ("Nomura" or the "Company") (NYSE: NMR). Investors are encouraged to reach out to Danielle Peyton at [email protected] or call 646-581-9980, ext.